Instinct Bio Technical Company Holdings Inc. (BIOT)
| Market Cap | 5.34M |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 28.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,343 |
| Open | 0.1929 |
| Previous Close | 0.1803 |
| Day's Range | 0.1800 - 0.1929 |
| 52-Week Range | 0.1660 - 50.0000 |
| Beta | -1.00 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BIOT
Instinct Bio Technical Company Holdings Inc. focuses on stem cell and regenerative medicine-related products, wellness, and beauty encompassing from research and development, manufacturing, branding, and distribution. It has a strategic collaboration with PT Parva Candela to develop cosmetics business in Indonesia. The company was founded in 2011 and is headquartered in Tokyo, Japan.
News
INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives
NEW YORK and TOKYO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.
Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
NEW YORK and TOKYO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) ("Instinct Bio" or the "Company") today announced a cooperation agreement with PT PARV...
BIOT to Launch Indonesia's First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia's Fastest-Growing Aesthetics Markets
BIOT to Launch Indonesia's First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” Building a Recurring-Revenue Platform
Relativity Acquisition Corp. SPAC and Instinct Bio Technical Co. Announce Effectiveness of Registration Statement
Las Vegas, NV, Tokyo, Japan, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Special purpose acquisition company, Relativity Acquisition Corp. (“Relativity”), and Instinct Bio Technical Company Inc. (“Instinct Bio”...
Relativity Acquisition Corp. Announces the Public Filing of a Registration Statement on Form F-4 for Instinct Bio Technical Company Inc.
Las Vegas, NV, Tokyo, Japan, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Relativity Acquisition Corp. (“Relativity”) today announced that on September 8, 2025, Instinct Bio Technical Company Inc. (“Instinct Bi...
Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment
NEW YORK , Jan. 4, 2023 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in connection with a pro...
Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement
NEW YORK and SOUTH SAN FRANCISCO, Calif. , June 13, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM...
Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination
Extraordinary General Meeting of BAC's shareholders postponed until a to-be-determined later date NEW YORK and SOUTH SAN FRANCISCO, Calif. , June 2, 2022 /PRNewswire/ -- Biotech Acquisition Company (N...
Biotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
NEW YORK , May 24, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (" BAC "), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today anno...
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ATS2022--Blade Therapeutics announces new data from preclinical studies that highlight differentiating characteristics of cudetaxestat in poster at ATS ...
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ATS2022--Blade Therapeutics presented data from phase 1 & preclinical DDI studies of cudetaxestat at American Thoracic Society 2022 International Confer...
Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity F
Extraordinary General Meeting of BAC's shareholders is scheduled for June 1, 2022, at 10:00 a.m., Eastern Time Post-closing company will be renamed "Blade Biotherapeutics, Inc." upon Business Combinat...
Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
NEW YORK , April 4, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (" BAC "), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today ann...
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #clinicalstudy--Blade Therapeutics, Inc. (“Blade” or “Company”), a biopharmaceutical company focused on developing cutting-edge treatments for debilitati...
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ATS2022--Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenera...
Biotech Acquisition Company Announces Public Filing of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
NEW YORK , March 16, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (" BAC "), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today an...
Blade Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #OPCOHC2022--Blade to present at Oppenheimer's 32nd Annual Healthcare Conference on March 15 and at Barclays Global Healthcare Conference on March 16, 20...
Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #clinicalstudy--Blade Therapeutics, Inc. today announced the successful completion of a phase 1 drug-drug interaction clinical study of cudetaxestat.
Biotech Acquisition Company Announces Confidential Submission of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
NEW YORK, Jan. 3, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (" BAC "), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today annou...
Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #clinicalstudy--Blade announces positive topline data from a phase 1 drug-drug interaction clinical study of cudetaxestat.